On October 8, several key developments in the tech and finance sectors were highlighted, reflecting shifting dynamics and investment opportunities.
During a session with Investing Club members, Nvidia CEO Jensen Huang addressed concerns regarding Oracle’s cloud business, asserting that renting Nvidia chips will prove “wonderfully profitable” over time for AI systems, despite recent reports suggesting thin margins for Oracle. This statement has implications for Nvidia’s partnerships in the growing AI market.
In another turn for Nvidia, AI cloud provider CoreWeave is reportedly poised to benefit from its legacy Nvidia chips. Contrary to prevailing opinions that older technology becomes obsolete quickly, CoreWeave’s use of these chips continues to drive significant data processing capabilities, potentially challenging skeptics of the company’s profitability.
Additionally, Nvidia is investing $2 billion into Elon Musk’s startup xAI, part of a larger $20 billion funding round. This move is expected to boost xAI’s capacity to procure Nvidia chips, raising questions about how interconnected these companies are in the competitive landscape of AI technology.
Amid the evolving tech environment, Melius Research expressed confidence in Broadcom, despite some analysts questioning the implications of chip deals with AMD and Nvidia. Melius maintained its buy rating, emphasizing Broadcom’s three years of revenue visibility in the AI space, thereby alleviating concerns about a potential AI market bubble.
In financial news, gold prices surpassed $4,000 an ounce for the first time, prompting discussions about the importance of gold ownership amidst rising U.S. government deficits. The CEO of Agnico Eagle, a top gold stock, is set to appear on “Mad Money,” where the potential for gold investment will be a topic of interest.
Barclays raised its price target for BlackRock to $1,310, reflecting solid organic growth prospects as the company prepares for its quarterly results. This positive outlook contrasts with adjustments made by Barclays on Blackstone, lowering its price target amid concerns over sustaining strong investments, emphasizing a need for cautious observation.
Meanwhile, Oklo, a nuclear technology company, has seen its stock rise again after a notable decrease last month. However, the company’s cash reserves remain a concern, initiating a “froth” watch for audiences interested in investment fluctuations.
Eli Lilly received an upward price target adjustment from Guggenheim, which raised it to $948, citing strong potential for its diabetes treatment, Mounjaro. This positions Eli Lilly as a vital player in the healthcare space, despite previous periods of inactivity.
Conversely, Bernstein cut its price target for McCormick to $93, raising alarms over potential margin shortfalls due to increasing tariff pressures. Despite this downgrade, Bernstein preserved its outperform rating, indicating a mixed outlook across various research firms.
For investors tracking these trends, a subscription to the CNBC Investing Club offers alerts on trades made by Jim Cramer, who carefully times his transactions based on prior recommendations and market movements. The insights from these reports are framed within clear terms and conditions, underscoring the inherent risks in investment activities.
